ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2660

Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis

Xia Zhang1 and Jing He2, 1Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, 2Rheumatology, Peking University People's Hospital, Beijing, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Interleukins (IL) and lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Lupus nephritis (LN) is a common and serious organ manifestation of SLE and is associated with substantial patient morbidity and mortality. The production of interleukin-2 (IL-2), a key cytokine that regulates the differentiation and activation of CD4+ T cell subsets, is impaired in LN patients. Previous studies have shown IL-2 can expand Treg cell numbers and reduce Tfh and Th17 effector CD4+ T cell subsets in SLE. However, the efficacy of low-dose IL-2 to refractory LN is still unclear.

Methods: We conducted a prospective, open-label study to evaluate the effects of low-dose rhIL-2 (recombinant human IL-2Ser125, Beijing SL Pharma) in patients with refractory LN. Three cycles of rhIL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks (a total of 7 doses), followed by a 2-week break. After the initiation of IL-2, no increase in any other treatments for SLE was permitted. Clinical and laboratory data were measured at baseline and every 4 weeks thereafter until week 12. Refractory disease was defined as no or incomplete response to conventional 2-drug immunosuppressive therapy. Ten patients with refractory LN were eligible in IL-2 group and 10 in Placebo Group.

Results:

Significant reductions of 24h proteinuria and urine erythrocyte (p<0.05)in IL-2 group compared with placebo group.Serum albumin also demonstrated improvement. Both C3 and C4 increased significantly at week 12(P<0.01). In addition, anti-dsDNA and Anti-Nuclear Ab titter decreased significantly(P<0.01). Immunological analysis revealed that low-dose rhIL-2 administration was associated with selective expansion of Treg cells and conversely with reductions of Tfh and Th17 cells.

Conclusion:

Low-dose IL-2 therapy was effective in refractory LN.


Disclosure: X. Zhang, None; J. He, None.

To cite this abstract in AMA style:

Zhang X, He J. Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/low-dose-interleukin-2-treatment-of-refractory-lupus-nephritis/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-interleukin-2-treatment-of-refractory-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences